欧盟HMA药品数据库(European Union HMA Authorisation of Medicines DataBase)
MR编号SE/H/2040/001
药品名称Ryaltris
活性成分
    • mometasone furoate 25.0 µg
    • olopatadine 600.0 µg
剂型Nasal spray, suspension
上市许可持有人Glenmark Pharmaceuticals s.r.o., Czech Republic
参考成员国 - 产品名称Sweden (SE)
互认成员国 - 产品名称
    • Norway (NO)
      Ryaltris
    • Finland (FI)
    • Poland (PL)
      Ryaltris Nasal Spray
    • Germany (DE)
      Ryaltris 25 Mikrogramm/600 Mikrogramm pro Sprühstoß Nasenspray, Suspension
    • Czechia (CZ)
      RYALTRIS Nasal Spray
    • Denmark (DK)
    • Romania (RO)
      RYALTRIS Nasal Spray 600 micrograms/25 micrograms per actuation
    • Belgium (BE)
      Ryaltris 25 microgrammes/pulvérisation + 600 microgrammes/ pulvérisation, suspension pour pulvérisation nasale
    • Slovakia (SK)
    • Netherlands (NL)
    • United Kingdom (Northern Ireland) (XI)
    • Ireland (IE)
    • Austria (AT)
      RYALTRIS 25 Mikrogramm/600 Mikrogramm pro Sprühstoß Nasenspray, Suspension
    • France (FR)
    • Spain (ES)
    • Italy (IT)
许可日期2021/04/13
最近更新日期2024/07/01
药物ATC编码
    • R01AD59 mometasone, combinations
申请类型
  • TypeLevel1:Known Active Substance
  • TypeLevel2:Initial Application
  • TypeLevel3:Fixed combination Art 10b Dir 2001/83/EC
  • TypeLevel4:Chemical Substance
  • TypeLevel5:Prescription Only
附件文件下载
市场状态Positive
©2006-2024 Drugfuture->European Union HMA Authorisation of Medicines DataBase